Holen Sie sich die Stockscreener-App
39.02
7.49%
2.72
Schlusskurs vom Vortag:
$36.30
Offen:
$36.36
24-Stunden-Volumen:
1.41M
Relative Volume:
1.33
Marktkapitalisierung:
$2.90B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-301.06M
KGV:
-8.0123
EPS:
-4.87
Netto-Cashflow:
$-248.01M
1W Leistung:
+7.05%
1M Leistung:
+30.96%
6M Leistung:
-11.86%
1J Leistung:
+88.41%
1-Tages-Spanne:
$36.24
$39.61
1-Wochen-Bereich:
$34.29
$39.61
52-Wochen-Spanne:
$20.19
$53.92
Springworks Therapeutics Inc Stock (SWTX) Company Profile
Firmenname
Springworks Therapeutics Inc
Sektor
Branche
Telefon
203-883-9490
Adresse
100 WASHINGTON BOULEVARD, STAMFORD, CT
Vergleichen Sie SWTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| SWTX | 39.02 | 2.90B | 0 | -301.06M | -248.01M | -4.87 |
| VRTX | 450.97 | 116.38B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 82.09B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.14B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.25B | 3.30B | -501.07M | 1.03B | 11.54 |
Springworks Therapeutics Inc Stock (SWTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-05 | Eingeleitet | Guggenheim | Buy |
| 2022-12-01 | Eingeleitet | BofA Securities | Buy |
| 2021-01-19 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-29 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2020-03-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-01-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-10-08 | Eingeleitet | Cowen | Outperform |
| 2019-10-08 | Eingeleitet | Goldman | Buy |
| 2019-10-08 | Eingeleitet | JP Morgan | Overweight |
| 2019-10-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Springworks Therapeutics Inc Aktie (SWTX) Neueste Nachrichten
SpringWorks Therapeutics Inc. (SWTX): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts - Insider Monkey
SpringWorks started at outperform by Evercore ahead of FDA decision - MSN
SpringWorks Therapeutics (NASDAQ:SWTX) Now Covered by Evercore ISI - MarketBeat
Does SpringWorks Therapeutics (SWTX) Have the Potential to Rally 92.68% as Wall Street Analysts Expect? - MSN
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark - MSN
Evercore ISI Group Initiates Coverage of SpringWorks Therapeutics (SWTX) with Outperform Recommendation - MSN
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Position Boosted by Victory Capital Management Inc. - MarketBeat
SpringWorks Therapeutics: Q3 Earnings Snapshot - AOL
Equities Analysts Set Expectations for SWTX FY2024 Earnings - Defense World
Wedbush Has Negative Forecast for SWTX FY2024 Earnings - Defense World
When (SWTX) Moves Investors should Listen - Stock Traders Daily
Analyst Estimates: Here's What Brokers Think Of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Report - Yahoo Finance
Here's What Analysts Are Forecasting For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Results - Simply Wall St
FY2024 Earnings Forecast for SWTX Issued By HC Wainwright - MarketBeat
Wedbush Has Negative Outlook for SWTX FY2024 Earnings - MarketBeat
SpringWorks Therapeutics Inc (SWTX) Quarterly 10-Q Report - Quartzy
Los Angeles Capital Management LLC Boosts Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
HC Wainwright Issues Pessimistic Forecast for SpringWorks Therapeutics (NASDAQ:SWTX) Stock Price - Defense World
SpringWorks Therapeutics (NASDAQ:SWTX) Releases Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q3 2024 Earnings Call Transcript - Insider Monkey
Principal Financial Group Inc. Has $29.43 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics Inc (SWTX) Q3 2024 Earnings Call Highli - GuruFocus.com
SpringWorks Therapeutics Inc (SWTX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
SpringWorks Therapeutics (NASDAQ:SWTX) Shares Gap Down on Analyst Downgrade - Defense World
SpringWorks Therapeutics Q3 2024 Results Overview - TipRanks
SpringWorks Therapeutics Inc (SWTX) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
SpringWorks Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - XM
HC Wainwright Cuts SpringWorks Therapeutics (NASDAQ:SWTX) Price Target to $74.00 - MarketBeat
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference - The Manila Times
SpringWorks Therapeutics to Present at Jefferies London Healthcare Conference | SWTX Stock News - StockTitan
SpringWorks Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
SpringWorks Therapeutics (SWTX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
SpringWorks Therapeutics’ mirdametinib shows efficacy in neurofibromatosis study - Yahoo Finance
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Bakersfield Californian
SOPHiA GENETICS (NASDAQ:SOPH) vs. SpringWorks Therapeutics (NASDAQ:SWTX) Financial Review - Defense World
Earnings To Watch: SpringWorks Therapeutics Inc (SWTX) Reports Q - GuruFocus.com
SpringWorks Therapeutics Announces Mirdametinib Data to be - GlobeNewswire
SpringWorks' Cancer Drug Shows Breakthrough 62% Response Rate, FDA Fast-Tracks Review | SWTX Stock News - StockTitan
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology - Quantisnow
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating - The Bakersfield Californian
SpringWorks Therapeutics Announces Publication of the - GlobeNewswire
SpringWorks' Mirdametinib Shows Breakthrough 52% Response Rate in NF1-PN Trial | SWTX Stock News - StockTitan
Creative Planning Takes $254,000 Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
SpringWorks Therapeutics (SWTX) Set to Announce Earnings on Tuesday - Defense World
Fiera Capital Corp Lowers Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Earns Outperform Rating from Wedbush - Defense World
Brokerages Set SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Price Target at $68.50 - Defense World
SpringWorks Therapeutics Announces Long-Term Efficacy and - GlobeNewswire
SpringWorks' OGSIVEO Shows 75.8% Tumor Reduction in 4-Year Treatment Data | SWTX Stock News - StockTitan
What's Going On With Rare Diseases-Focused SpringWorks Therapeutics Stock Today? - MSN
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Finanzdaten der Springworks Therapeutics Inc-Aktie (SWTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
2.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):